Allopregnanolone

Phase 2Small molecule

UUniversity of Arizona

Allopregnanolone is one of 2 small molecule programs targeting Alzheimer Dementia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DementiaActive, not recruiting

Alzheimer DementiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Alzheimer Dementia

#DrugCompanyPhaseTrials

Allopregnanolone

UUniversity of Arizona

Phase 2

1 2

Buntanetap/posiphen

AAnnovis Bio Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Alzheimer Dementia

NCT04838301

Q2 2027

Phase 2Not yet recruiting

Traumatic Brain Injury (TBI)

NCT04003285

Clinical

Trials by Indication[1]

Cognitive impairment1 trial

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

Completed·UUniversity of Southern California·Phase 1·NCT02221622·24 enrolled

Brain Injury1 trial

Allopregnanolone for the Treatment of Traumatic Brain Injury

Completed·MMichael A. Rogawski, MD, PhD·Phase 2·NCT01673828·13 enrolled

Parkinson's Disease1 trial

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

Completed·RRoberta Brinton·Phase 1·NCT06263010·10 enrolled

Craving1 trial

Effect of Allopregnanolone on Stress-induced Craving

Completed·YYale University·Phase 1·NCT04015869·10 enrolled

Early Alzheimer's Disease1 trial

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

Terminated·UUniversity of Arizona·Phase 1·NCT03748303·6 enrolled

3 more indications

Ataxia1 trial

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

Completed·RRandi J. Hagerman, MD·Phase 2·NCT02603926·6 enrolled

Traumatic Brain Injury (TBI)1 trial

Novel Regenerative Therapeutic in Chronic Complex TBI

Not yet recruiting·VVA Office of Research and Development·Phase 2·NCT04003285·132 enrolled

Alzheimer Dementia1 trial

Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial

Active, not recruiting·UUniversity of Arizona·Phase 2·NCT04838301·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Allopregnanolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allopregnanolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allopregnanolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Arizona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Arizona

Allopregnanolone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Cognitive impairment1 trial

Brain Injury1 trial

Parkinson's Disease1 trial

Craving1 trial

Early Alzheimer's Disease1 trial

Ataxia1 trial

Traumatic Brain Injury (TBI)1 trial

Alzheimer Dementia1 trial

References

Drug Info

Quick Facts

Related News